Delaware | 1-14064 | 11-2408943 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
767 Fifth Avenue, New York, New York |
10153 | |||||||||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Class A Common Stock, $.01 par value | EL | New York Stock Exchange |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Exhibit No. | Description | ||||||||||
99.1 | |||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
THE ESTÉE LAUDER COMPANIES INC. | |||||||||||
Date: | August 18, 2022 |
By: | /s/ Tracey T. Travis | ||||||||
Tracey T. Travis | |||||||||||
Executive Vice President and Chief Financial Officer | |||||||||||
(Principal Financial and Accounting Officer) |
![]() 767 Fifth Avenue
New York, NY 10153
|
News
Contact:
Investors: Rainey Mancini
rmancini@estee.com
Media: Jill Marvin
jimarvin@estee.com
|
![]() |
Page 1 of 24
|
Reconciliation between GAAP and Non-GAAP Net Sales Growth (Unaudited) | |||||
Year Ended
June 30, 2022
|
|||||
As Reported - GAAP(1) |
9 | % | |||
Organic, Non-GAAP(2) |
8 | % | |||
Impact of acquisitions, divestitures and brand closures, net | 2 | ||||
Impact of foreign currency translation | (1) | ||||
Returns associated with restructuring and other activities | — | ||||
As Reported - GAAP(1) |
9 | % | |||
(1)Includes returns associated with restructuring and other activities |
|||||
(2)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (notably DECIEM and BECCA); as well as the impact of currency translation. |
![]() |
Page 2 of 24
|
Reconciliation between GAAP and Non-GAAP - Diluted Earnings Per Share (“EPS”) (Unaudited) | |||||||||||
Year Ended June 30 | |||||||||||
2022 | 2021 | Growth | |||||||||
As Reported EPS - GAAP(1) |
$ | 6.55 | $ | 7.79 | (16) | % | |||||
Non-GAAP | |||||||||||
Restructuring and other charges | .31 | .48 | |||||||||
Changes in fair value of contingent consideration | — | (.01) | |||||||||
Change in fair value of acquisition-related stock options (less the portion attributable to redeemable noncontrolling interest) | (.12) | .09 | |||||||||
Goodwill, other intangible and long-lived asset impairments | .50 | .40 | |||||||||
Other income | — | (2.30) | |||||||||
Adjusted EPS - Non-GAAP | $ | 7.24 | $ | 6.45 | 12 | % | |||||
Impact of foreign currency translation on earnings per share | (.04) | ||||||||||
Adjusted Constant Currency EPS - Non-GAAP | $ | 7.20 | 12 | % | |||||||
(1)Includes restructuring and other charges and adjustments |
|||||||||||
![]() |
Page 3 of 24
|
Results by Product Category (Unaudited) | |||||||||||||||||||||||
Year Ended June 30 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) |
Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
Skin Care | $ | 9,886 | $ | 9,484 | 4 | % | 4 | % | $ | 2,753 | $ | 3,036 | (9) | % | |||||||||
Makeup | 4,667 | 4,203 | 11 | 12 | 133 | (384) | 100+ | ||||||||||||||||
Fragrance | 2,508 | 1,926 | 30 | 32 | 456 | 215 | 100+ | ||||||||||||||||
Hair Care | 631 | 571 | 11 | 12 | (28) | (19) | (47) | ||||||||||||||||
Other | 49 | 45 | 9 | 9 | — | (2) | 100 | ||||||||||||||||
Subtotal | $ | 17,741 | $ | 16,229 | 9 | % | 10 | % | $ | 3,314 | $ | 2,846 | 16% | ||||||||||
Returns/charges associated with restructuring and other activities | (4) | (14) | (144) | (228) | |||||||||||||||||||
Total | $ | 17,737 | $ | 16,215 | 9 | % | 10 | % | $ | 3,170 | $ | 2,618 | 21 | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Year Ended June 30
2022 vs. 2021
|
||||||||||||||
Organic
Net Sales Growth
(Non-GAAP)(1)
|
Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) |
|||||||||||
Skin Care | — | % | 4 | % | — | % | 4 | % | ||||||
Makeup | 12 | — | (1) | 11 | ||||||||||
Fragrance | 32 | — | (2) | 30 | ||||||||||
Hair Care | 12 | — | (1) | 11 | ||||||||||
Other | 4 | 5 | — | 9 | ||||||||||
Subtotal | 8 | % | 2 | % | (1) | % | 9 | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | 8 | % | 2 | % | (1) | % | 9 | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (notably DECIEM and BECCA); as well as the impact of currency translation. |
![]() |
Page 4 of 24
|
![]() |
Page 5 of 24
|
Results by Geographic Region (Unaudited) | |||||||||||||||||||||||
Year Ended June 30 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
The Americas | $ | 4,623 | $ | 3,797 | 22 | % | 21 | % | $ | 1,159 | $ | 518 | 100+% | ||||||||||
Europe, the Middle East & Africa | 7,681 | 6,946 | 11 | 12 | 1,360 | 1,335 | 2 | ||||||||||||||||
Asia/Pacific | 5,437 | 5,486 | (1) | (1) | 795 | 993 | (20) | ||||||||||||||||
Subtotal | $ | 17,741 | $ | 16,229 | 9 | % | 10 | % | $ | 3,314 | $ | 2,846 | 16% | ||||||||||
Returns/charges associated with restructuring and other activities | (4) | (14) | (144) | (228) | 37 | ||||||||||||||||||
Total | $ | 17,737 | $ | 16,215 | 9 | % | 10 | % | $ | 3,170 | $ | 2,618 | 21 | % |
![]() |
Page 6 of 24
|
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Year Ended June 30
2022 vs. 2021
|
||||||||||||||
Organic
Net Sales Growth
(Non-GAAP)(1)
|
Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) |
|||||||||||
The Americas | 16 | % | 5 | % | 1 | % | 22 | % | ||||||
Europe, the Middle East & Africa | 10 | 2 | (1) | 11 | ||||||||||
Asia/Pacific | (2) | 1 | — | (1) | ||||||||||
Subtotal | 8 | % | 2 | % | (1) | % | 9 | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | 8 | % | 2 | % | (1) | % | 9 | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (notably DECIEM and BECCA); as well as the impact of currency translation. |
![]() |
Page 7 of 24
|
![]() |
Page 8 of 24
|
![]() |
Page 9 of 24
|
![]() |
Page 10 of 24
|
![]() |
Page 11 of 24
|
Reconciliation between GAAP and Non-GAAP - Net Sales Growth (Unaudited) | ||||||||
Three Months Ending | Twelve Months Ending | |||||||
September 30, 2022(F) |
June 30, 2023(F) |
|||||||
As Reported - GAAP(1) |
(10%) - (8%) | 3% - 5% | ||||||
Organic, Non-GAAP(2) |
(6%) - (4%) | 7% - 9% | ||||||
Impact of acquisitions, divestitures and brand closures | (1) | (1) | ||||||
Impact of foreign currency translation | (3) | (3) | ||||||
Returns associated with restructuring and other activities | — | — | ||||||
As Reported - GAAP(1) |
(10%) - (8%) | 3% - 5% | ||||||
(1)Includes returns associated with restructuring and other activities | ||||||||
(2)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of already announced acquisitions, divestitures and brand closures (i.e., certain of your designer fragrances); as well as the impact of currency translation. | ||||||||
(F)Represents forecast |
Reconciliation between GAAP and Non-GAAP - Diluted Earnings Per Share (“EPS”) (Unaudited) | ||||||||||||||||||||
Three Months Ending | Twelve Months Ending | |||||||||||||||||||
September 30 | June 30 | |||||||||||||||||||
2022(F) |
2021 | Growth | 2023(F) |
2022 | Variance | |||||||||||||||
Forecasted/As Reported EPS - GAAP(1) |
$1.16 - $1.28 | $ | 1.88 | (38%) - (32%) | $7.11 - $7.33 | $ | 6.55 | 9% - 12% | ||||||||||||
Non-GAAP | ||||||||||||||||||||
Restructuring and other charges | .04 - .06 | .01 | .21 - .28 | .31 | ||||||||||||||||
Change in fair value of acquisition-related stock options (less the portion attributable to redeemable noncontrolling interest) | — | — | — | (.12) | ||||||||||||||||
Other intangible and long-lived asset impairments | — | — | — | .50 | ||||||||||||||||
Forecasted/Adjusted EPS - Non-GAAP | $1.22- $1.32 | $ | 1.89 | (36%) - (30%) | $7.39 - $7.54 | $ | 7.24 | 2% - 4% | ||||||||||||
Impact of foreign currency translation | .04 | .20 | ||||||||||||||||||
Forecasted Adjusted Constant Currency EPS - Non-GAAP | $1.26 - $1.36 | (34%) - (28%) | $7.59 - $7.74 | 5% - 7% | ||||||||||||||||
(1)Includes restructuring and other charges and adjustments | ||||||||||||||||||||
(F)Represents forecast |
![]() |
Page 12 of 24
|
![]() |
Page 13 of 24
|
![]() |
Page 14 of 24
|
CONSOLIDATED STATEMENT OF EARNINGS (Unaudited) | |||||||||||||||||||||||
Three Months Ended June 30 |
Percentage Change | Year Ended June 30 |
Percentage Change | ||||||||||||||||||||
($ in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net sales(A) |
$ | 3,561 | $ | 3,936 | (10) | % | $ | 17,737 | $ | 16,215 | 9 | % | |||||||||||
Cost of sales(A) |
1,031 | 986 | 5 | 4,305 | 3,834 | 12 | |||||||||||||||||
Gross profit | 2,530 | 2,950 | (14) | 13,432 | 12,381 | 8 | |||||||||||||||||
Gross margin | 71.0 | % | 74.9 | % | 75.7 | % | 76.4 | % | |||||||||||||||
Operating expenses | |||||||||||||||||||||||
Selling, general and administrative(B) |
2,334 | 2,610 | (11) | 9,888 | 9,371 | 6 | |||||||||||||||||
Restructuring and other charges(A) |
92 | 32 | 100+ | 133 | 204 | (35) | |||||||||||||||||
Goodwill impairment(C) |
— | — | — | — | 54 | (100) | |||||||||||||||||
Impairment of other intangible and long-lived assets(C) |
25 | 74 | (66) | 241 | 134 | 80 | |||||||||||||||||
Total operating expenses | 2,451 | 2,716 | (10) | 10,262 | 9,763 | 5 | |||||||||||||||||
Operating expense margin | 68.8 | % | 69.0 | % | 57.9 | % | 60.2 | % | |||||||||||||||
Operating income | 79 | 234 | (66) | 3,170 | 2,618 | 21 | |||||||||||||||||
Operating income margin | 2.2 | % | 5.9 | % | 17.9 | % | 16.1 | % | |||||||||||||||
Interest expense | 42 | 42 | — | 167 | 173 | (3) | |||||||||||||||||
Interest income and investment income, net | 11 | 11 | — | 30 | 51 | (41) | |||||||||||||||||
Other components of net periodic benefit cost | — | — | — | (2) | 12 | (100+) | |||||||||||||||||
Other income(D) |
— | 847 | (100) | 1 | 847 | (100) | |||||||||||||||||
Earnings before income taxes | 48 | 1,050 | (95) | 3,036 | 3,331 | (9) | |||||||||||||||||
Provision for income taxes | (2) | 35 | (100+) | 628 | 456 | 38 | |||||||||||||||||
Net earnings | 50 | 1,015 | (95) | 2,408 | 2,875 | (16) | |||||||||||||||||
Net earnings(loss) attributable to noncontrolling interests | 1 | (4) | 100+ | (7) | (12) | 42 | |||||||||||||||||
Net earnings(loss) attributable to redeemable noncontrolling interest | 1 | 7 | (86) | (11) | 7 | (100+) | |||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 52 | $ | 1,018 | (95) | % | $ | 2,390 | $ | 2,870 | (17) | % | |||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. per common share | |||||||||||||||||||||||
Basic | $ | .15 | $ | 2.81 | (95) | % | $ | 6.64 | $ | 7.91 | (16) | % | |||||||||||
Diluted | $ | .14 | $ | 2.76 | (95) | % | $ | 6.55 | $ | 7.79 | (16) | % | |||||||||||
Weighted-average common shares outstanding | |||||||||||||||||||||||
Basic | 358.0 | 362.9 | 360.0 | 362.9 | |||||||||||||||||||
Diluted | 361.6 | 368.5 | 364.9 | 368.2 | |||||||||||||||||||
![]() |
Page 15 of 24
|
(A)In August 2020, the Company announced a two-year restructuring program, Post-COVID Business Acceleration Program (the “PCBA Program”), designed to realign its business to address the dramatic shifts to its distribution landscape and consumer behaviors in the wake of the COVID-19 pandemic. The PCBA Program will help improve efficiency and effectiveness by rebalancing resources to growth areas of prestige beauty. It will further strengthen the Company by building upon the foundational capabilities in which the Company has invested. The PCBA Program’s main areas of focus include accelerating the shift to online with the realignment of the Company’s distribution network reflecting freestanding store and certain department store closures, with a focus on North America and Europe, the Middle East & Africa; the reduction in brick-and-mortar point of sale employees and related support staff; and the redesign of the Company’s regional branded marketing organizations, plus select opportunities in global brands and functions. This program is expected to position the Company to better execute its long-term strategy while strengthening its financial flexibility. The Company plans to approve specific initiatives under the PCBA Program through fiscal 2022 and expects to substantially complete those initiatives through fiscal 2023. The Company expects that the PCBA Program will result in related restructuring and other charges totaling between $500 million and $515 million, before taxes.
The Company substantially completed initiatives approved under the Leading Beauty Program (the “LBF Program”) through fiscal 2021. Additional information about the LBF Program is included in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
| ||||||||||||||
(B)For the three and twelve months ended June 30, 2022, the Company recorded $3 million ($3 million, less the portion attributable to redeemable noncontrolling interest and net of tax, or $.01 per common share) and $(55) million ($(43) million, less the portion attributable to redeemable noncontrolling interest and net of tax, or ($.12) per common share), respectively, of expense(income) related to the change in fair value of acquisition-related stock options related to DECIEM. For the twelve months ended June 30, 2021, the Company recorded $40 million ($31 million, less portion attributable to redeemable noncontrolling interest and net of tax, or $.09 per common share) of acquisition-related stock option expense related to DECIEM stock options.
The Company recorded $2 million ($2 million, net of tax) of income within selling, general and administrative expenses for the three and twelve months ended June 30, 2021 to reflect changes in the fair value of its contingent consideration related to its fiscal 2016 acquisition.
| ||||||||||||||
(C)During the fiscal 2022 third quarter, given the lower-than-expected results from international expansion to areas that continue to be impacted by COVID-19, the Company made revisions to the internal forecasts relating to its GLAMGLOW reporting unit. The Company concluded that the changes in circumstances in the reporting unit triggered the need for an interim impairment review of its trademark intangible asset.
During the fiscal 2022 third quarter, given the lower-than-expected growth within key geographic regions and channels for Dr.Jart+ that continue to be impacted by the spread of COVID-19 variants and resurgence in cases and the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the financial performance of the brand, the lower than expected growth in key retail channels for DECIEM, and the lower than expected results from international expansion to areas that continue to be impacted by COVID-19 for Too Faced, the Company made revisions to the internal forecasts relating to its Dr.Jart+, DECIEM and Too Faced reporting units.
The Company concluded that the changes in circumstances in the reporting units triggered the need for interim impairment reviews of their trademarks and goodwill. These changes in circumstances were also an indicator that the carrying amounts of Dr.Jart+’s, DECIEM’s and Too Faced’s long-lived assets, including customer lists, may not be recoverable. Accordingly, the Company performed interim impairment tests for the trademarks and a recoverability test for the long-lived assets as of February 28, 2022. The Company concluded that the carrying amounts of the long-lived assets were recoverable. For the Dr.Jart+ reporting unit, the Company also concluded that the carrying value of the trademark intangible asset exceeded its estimated fair value and recorded an impairment charge. For the Too Faced and DECIEM reporting units, as the carrying values of the trademarks did not exceed their estimated fair values the Company did not record impairment charges. After adjusting the carrying values of the trademarks, the Company completed interim quantitative impairment tests for goodwill. As the estimated fair value of the Dr.Jart+, DECIEM and Too Faced reporting units were in excess of their carrying values, the Company concluded that the carrying amounts of the goodwill were recoverable and did not record a goodwill impairment charge related to these reporting units.
During the fiscal 2022 fourth quarter, based on the Company’s annual goodwill and other indefinite-lived intangible asset impairment testing as of April 1, 2022, the Company determined that the carrying value of the Dr.Jart+ trademark exceeded its fair value. This determination was made based on updated internal forecasts. Given the lower-than-expected growth within key geographic regions and channels that continued to be impacted by the spread of COVID-19 variants, the resurgence in cases, regional lockdowns and the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the financial performance of the brand, we made revisions to the internal forecasts relating to the Dr.Jart+ reporting unit. These changes in circumstances were also indicators that the carrying amounts of their respective long-lived assets may not be recoverable. The Company concluded that the carrying value of the trademark intangible asset exceeded its estimated fair value. The Company concluded that the carrying amount of the long-lived assets were recoverable. For the three months ended June 30, 2022, the Company recognized other intangible asset impairment charges of $25 million ($19 million, net of tax, or $.05 per common share) relating to the Dr.Jart+ reporting unit.
The total other intangible asset impairment charges recorded for the twelve months ended June 30, 2022 were $241 million ($183 million, net of tax), with an impact of $.50 per common share.
|
![]() |
Page 16 of 24
|
During November 2020, given the actual and the estimate of the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the Company and lower than expected results from geographic expansion, the Company made further revisions to the internal forecasts relating to its GLAMGLOW reporting unit, triggering a need for an interim impairment review.
During the fiscal 2021 fourth quarter, based on the Company’s annual goodwill and other indefinite-lived intangible asset impairment testing as of April 1, 2021, the Company determined that the carrying value of the GLAMGLOW and Smashbox trademarks exceeded their fair values. This determination was made based on updated internal forecasts, finalized and approved in June 2021, that reflected lower net sales growth projections due to a softer than expected retail environment for these brands, as well as the continued impacts relating to the uncertainty of the duration and severity of the COVID-19 pandemic. These changes in circumstances were also indicators that the carrying amounts of their respective long-lived assets may not be recoverable. The Company concluded that the carrying values of the trademarks exceeded their estimated fair values. The Company concluded that the carrying amounts of the long-lived assets were recoverable. For the three months ended June 30, 2021, the Company recognized other intangible asset impairment charges of $36 million ($27 million, net of tax, or $.08 per common share) relating to these reporting units.
The total goodwill and other intangible asset impairment charges recorded for the twelve months ended June 30, 2021 were $117 million ($91 million, net of tax, or $.25 per common share).
During March 2021, the Company recognized long-lived asset impairments related to other assets (i.e. rights associated with commercial operating leases), operating lease ROU assets and the related property, plant and equipment in certain freestanding stores primarily in Europe due to the impact of the COVID-19 pandemic.
During the fiscal 2021 fourth quarter, the Company also recognized $38 million ($31million, net of tax, or $.08 per common share) of long-lived asset impairments, included in Impairments of other intangible and long-lived assets, in the accompanying consolidated statements of earnings (loss) for the three months ended June 30, 2021, related to operating lease ROU assets of $21 million, as well as the related property, plant and equipment and other long-lived assets in certain freestanding stores of $16 million, combined.
The total long-lived asset impairment charges recognized for the twelve months ended June 30, 2021 were $71 million ($57 million, net of tax, or $.15 per common share), related to other assets (i.e. rights associated with commercial operating leases) of $27 million, operating lease ROU assets of $25 million, as well as the related property, plant and equipment in certain freestanding stores of $19 million.
| ||||||||||||||
For the three and twelve months ended June 30, 2021, total goodwill, other intangible and long-lived asset impairment charges were $74 million ($58 million, net of tax, or $.16 per common share) and $188 million ($148 million, net of tax, or $.40 per common share), respectively. | ||||||||||||||
(D)In conjunction with the increased investment in DECIEM in May 2021, the Company recorded a gain on its previously held equity method investment of $847 million ($847 million, net of tax) which had an impact of $2.30 per common share for the three and twelve months ended June 30, 2021. |
![]() |
Page 17 of 24
|
Returns and Charges Associated With Restructuring and Other Activities and Other Adjustments (Unaudited) | |||||||||||||||||||||||
Three Months Ended June 30, 2022 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges |
Other Charges/ Adjustments |
|||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | — | $ | 1 | $ | 3 | $ | 4 | $ | 3 | $ | .01 | |||||||||
PCBA Program | 1 | 7 | 85 | 3 | 96 | 76 | .21 | ||||||||||||||||
Change in fair value of acquisition-related stock options | 3 | 3 | 3 | .01 | |||||||||||||||||||
Other intangible asset impairments | 25 | 25 | 19 | .05 | |||||||||||||||||||
Total | $ | 1 | $ | 7 | $ | 86 | $ | 34 | $ | 128 | $ | 101 | $ | .28 | |||||||||
Year Ended June 30, 2022 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges |
Other Charges/ Adjustments |
|||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | 2 | $ | (1) | $ | 16 | $ | 17 | $ | 13 | $ | .04 | |||||||||
PCBA Program | 4 | 5 | 109 | 9 | 127 | 100 | .27 | ||||||||||||||||
Change in fair value of acquisition-related stock options | (55) | (55) | (43) | (.12) | |||||||||||||||||||
Other intangible asset impairments | 241 | 241 | 183 | .50 | |||||||||||||||||||
Other income | (1) | (1) | (1) | — | |||||||||||||||||||
Total | $ | 4 | $ | 7 | $ | 108 | $ | 210 | $ | 329 | $ | 252 | $ | .69 | |||||||||
Three Months Ended June 30, 2021 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges |
Other Charges/ Adjustments |
|||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | 4 | $ | (8) | $ | 5 | $ | 1 | $ | 1 | $ | — | |||||||||
PCBA Program | 4 | (3) | 34 | 1 | 36 | 26 | .07 | ||||||||||||||||
Changes in fair value of contingent consideration | — | — | — | — | |||||||||||||||||||
Acquisition-related stock option expense | 40 | 40 | 31 | .09 | |||||||||||||||||||
Goodwill, other intangible and long-lived asset impairments | 74 | 74 | 58 | .16 | |||||||||||||||||||
Other income | (847) | (847) | (847) | (2.30) | |||||||||||||||||||
Total | $ | 4 | $ | 1 | $ | 26 | $ | (727) | $ | (696) | $ | (731) | $ | (1.98) | |||||||||
Year Ended June 30, 2021 | |||||||||||||||||||||||
Sales Returns | Cost of Sales | Operating Expenses | Total | After Redeemable Noncontrolling Interest and Tax | Diluted EPS | ||||||||||||||||||
(In millions, except per share data) | Restructuring Charges |
Other Charges/ Adjustments |
|||||||||||||||||||||
Leading Beauty Forward | $ | — | $ | 8 | $ | (15) | $ | 14 | $ | 7 | $ | 6 | $ | .02 | |||||||||
PCBA Program | 14 | 2 | 201 | 4 | 221 | 170 | .46 | ||||||||||||||||
Changes in fair value of contingent consideration | (2) | (2) | (2) | (.01) | |||||||||||||||||||
Acquisition-related stock option expense | 40 | 40 | 31 | .09 | |||||||||||||||||||
Goodwill, other intangible and long-lived asset impairments | 188 | 188 | 148 | .40 | |||||||||||||||||||
Other income | (847) | (847) | (847) | (2.30) | |||||||||||||||||||
Total | $ | 14 | $ | 10 | $ | 186 | $ | (603) | $ | (393) | $ | (494) | $ | (1.34) |
![]() |
Page 18 of 24
|
Results by Product Category (Unaudited) | |||||||||||||||||||||||
Three Months Ended June 30 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
Skin Care | $ | 1,883 | $ | 2,371 | (21) | % | (18) | % | $ | 287 | $ | 583 | (51) | % | |||||||||
Makeup | 993 | 960 | 3 | 7 | (95) | (269) | 65 | ||||||||||||||||
Fragrance | 521 | 448 | 16 | 22 | 10 | (33) | 100+ | ||||||||||||||||
Hair Care | 156 | 153 | 2 | 5 | (20) | (9) | (100+) | ||||||||||||||||
Other | 9 | 8 | 13 | 13 | (3) | (1) | (100+) | ||||||||||||||||
Subtotal | $ | 3,562 | $ | 3,940 | (10) | % | (7) | % | $ | 179 | $ | 271 | (34) | % | |||||||||
Returns/charges associated with restructuring and other activities | (1) | (4) | (100) | (37) | |||||||||||||||||||
Total | $ | 3,561 | $ | 3,936 | (10) | % | (7) | % | $ | 79 | $ | 234 | (66) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Three Months Ended June 2022 vs. 2021 |
||||||||||||||
Organic
Net Sales Growth
(Non-GAAP)(1)
|
Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) |
|||||||||||
Skin Care | (21) | % | 3 | % | (3) | % | (21) | % | ||||||
Makeup | 8 | (1) | (4) | 3 | ||||||||||
Fragrance | 22 | — | (6) | 16 | ||||||||||
Hair Care | 5 | — | (3) | 2 | ||||||||||
Other | 13 | — | — | 13 | ||||||||||
Subtotal | (8) | % | 1 | % | (3) | % | (10) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (8) | % | 1 | % | (3) | % | (10) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (notably DECIEM and BECCA); as well as the impact of currency translation. |
![]() |
Page 19 of 24
|
Results by Geographic Region (Unaudited) | |||||||||||||||||||||||
Three Months Ended June 30 | |||||||||||||||||||||||
Net Sales | Percentage Change | Operating Income (Loss) | Percentage Change | ||||||||||||||||||||
($ in millions) | 2022 | 2021 | Reported Basis | Constant Currency | 2022 | 2021 | Reported Basis | ||||||||||||||||
The Americas | $ | 1,076 | $ | 960 | 12 | % | 11 | % | $ | 115 | $ | 262 | (56) | % | |||||||||
Europe, the Middle East & Africa | 1,480 | 1,670 | (11) | (7) | (6) | (94) | 94 | ||||||||||||||||
Asia/Pacific | 1,006 | 1,310 | (23) | (19) | 70 | 103 | (32) | ||||||||||||||||
Subtotal | $ | 3,562 | $ | 3,940 | (10) | % | (7) | % | $ | 179 | $ | 271 | (34) | % | |||||||||
Returns/charges associated with restructuring and other activities | (1) | (4) | (100) | (37) | |||||||||||||||||||
Total | $ | 3,561 | $ | 3,936 | (10) | % | (7) | % | $ | 79 | $ | 234 | (66) | % |
Organic Net Sales Growth - Reconciliation to GAAP (Unaudited) | ||||||||||||||
Three Months Ended June 30 2022 vs. 2021 |
||||||||||||||
Organic
Net Sales Growth
(Non-GAAP)(1)
|
Impact of Acquisitions, Divestitures and Brand Closures, Net | Impact of Foreign Currency Translation | Net Sales Growth (GAAP) |
|||||||||||
The Americas | 9 | % | 2 | % | 1 | % | 12 | % | ||||||
Europe, the Middle East & Africa | (9) | 2 | (4) | (11) | ||||||||||
Asia/Pacific | (19) | — | (4) | (23) | ||||||||||
Subtotal | (8) | % | 1 | % | (3) | % | (10) | % | ||||||
Returns associated with restructuring and other activities | — | |||||||||||||
Total | (8) | % | 1 | % | (3) | % | (10) | % | ||||||
(1)Organic net sales growth represents net sales growth excluding returns associated with restructuring and other activities; non-comparable impacts of acquisitions, divestitures and brand closures (notably DECIEM and BECCA); as well as the impact of currency translation. |
![]() |
Page 20 of 24
|
Reconciliation of Certain Consolidated Statements of Earnings Accounts Before and After Returns, Charges and Other Adjustments (Unaudited) | ||||||||||||||||||||||||||||||||
Three Months Ended June 30 | ||||||||||||||||||||||||||||||||
2022 | 2021 | % Change | ||||||||||||||||||||||||||||||
($ in millions, except per share data) | As Reported | Returns/ Charges/ Adjustments |
Non-GAAP | Impact of Foreign Currency Translation | Non-GAAP, Constant Currency |
As Reported | Returns/ Charges/ Adjustments |
Non-GAAP | Non-GAAP | Non-GAAP, Constant Currency |
||||||||||||||||||||||
Net sales | $ | 3,561 | $ | 1 | $ | 3,562 | $ | 120 | $ | 3,682 | $ | 3,936 | $ | 4 | $ | 3,940 | (10) | % | (7) | % | ||||||||||||
Cost of sales | 1,031 | (7) | 1,024 | 33 | 1,057 | 986 | (1) | 985 | ||||||||||||||||||||||||
Gross profit | 2,530 | 8 | 2,538 | 87 | 2,625 | 2,950 | 5 | 2,955 | (14) | % | (11) | % | ||||||||||||||||||||
Gross margin | 71.0 | % | 71.3 | % | 71.3 | % | 74.9 | % | 75.0 | % | ||||||||||||||||||||||
Operating expenses | 2,451 | (120) | 2,331 | 85 | 2,416 | 2,716 | (146) | 2,570 | (9) | % | (6) | % | ||||||||||||||||||||
Operating expense margin | 68.8 | % | 65.4 | % | 65.6 | % | 69.0 | % | 65.2 | % | ||||||||||||||||||||||
Operating income | 79 | 128 | 207 | 2 | 209 | 234 | 151 | 385 | (46) | % | (46) | % | ||||||||||||||||||||
Operating income margin | 2.2 | % | 5.8 | % | 5.7 | % | 5.9 | % | 9.8 | % | ||||||||||||||||||||||
Other income | — | — | — | — | — | 847 | (847) | — | — | % | — | % | ||||||||||||||||||||
Provision(benefit) for income taxes | (2) | 27 | 25 | 1 | 26 | 35 | 26 | 61 | (59) | % | (57) | % | ||||||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 52 | $ | 101 | $ | 153 | $ | 2 | $ | 155 | $ | 1,018 | $ | (731) | $ | 287 | (47) | % | (46) | % | ||||||||||||
Diluted EPS | $ | .14 | $ | .28 | $ | .42 | $ | .01 | $ | .43 | $ | 2.76 | $ | (1.98) | $ | .78 | (46) | % | (45) | % | ||||||||||||
![]() |
Page 21 of 24
|
Reconciliation of Certain Consolidated Statements of Earnings Accounts Before and After Returns, Charges and Other Adjustments (Unaudited) | ||||||||||||||||||||||||||||||||
Year Ended June 30 | ||||||||||||||||||||||||||||||||
2022 | 2021 | % Change | ||||||||||||||||||||||||||||||
($ in millions, except per share data) | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Impact of Foreign Currency Translation | Non-GAAP, Constant Currency | As Reported | Returns/ Charges/ Adjustments | Non-GAAP | Non-GAAP | Non-GAAP, Constant Currency | ||||||||||||||||||||||
Net sales | $ | 17,737 | $ | 4 | $ | 17,741 | $ | 88 | $ | 17,829 | $ | 16,215 | $ | 14 | $ | 16,229 | 9 | % | 10 | % | ||||||||||||
Cost of sales | 4,305 | (7) | 4,298 | 29 | 4,327 | 3,834 | (10) | 3,824 | ||||||||||||||||||||||||
Gross profit | 13,432 | 11 | 13,443 | 59 | 13,502 | 12,381 | 24 | 12,405 | 8 | % | 9 | % | ||||||||||||||||||||
Gross margin | 75.7 | % | 75.8 | % | 75.7 | % | 76.4 | % | 76.4 | % | ||||||||||||||||||||||
Operating expenses | 10,262 | (319) | 9,943 | 80 | 10,023 | 9,763 | (430) | 9,333 | 7 | % | 7 | % | ||||||||||||||||||||
Operating expense margin | 57.9 | % | 56.0 | % | 56.2 | % | 60.2 | % | 57.5 | % | ||||||||||||||||||||||
Operating income | 3,170 | 330 | 3,500 | (21) | 3,479 | 2,618 | 454 | 3,072 | 14 | % | 13 | % | ||||||||||||||||||||
Operating income margin | 17.9 | % | 19.7 | % | 19.5 | % | 16.1 | % | 18.9 | % | ||||||||||||||||||||||
Other income | 1 | (1) | — | — | — | 847 | (847) | — | — | % | — | % | ||||||||||||||||||||
Provision for income taxes | 628 | 89 | 717 | (5) | 712 | 456 | 92 | 548 | 31 | % | 30 | % | ||||||||||||||||||||
Net earnings attributable to The Estée Lauder Companies Inc. | $ | 2,390 | $ | 252 | $ | 2,642 | $ | (14) | $ | 2,628 | $ | 2,870 | $ | (494) | $ | 2,376 | 11 | % | 11 | % | ||||||||||||
Diluted EPS | $ | 6.55 | $ | .69 | $ | 7.24 | $ | (.04) | $ | 7.2 | $ | 7.79 | $ | (1.34) | $ | 6.45 | 12 | % | 12 | % |
![]() |
Page 22 of 24
|
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, except where noted) | ||||||||
June 30, 2022 | June 30, 2021 | |||||||
($ in millions) | (Audited) | |||||||
ASSETS | ||||||||
Cash and cash equivalents | $ | 3,957 | $ | 4,958 | ||||
Accounts receivable, net | 1,629 | 1,702 | ||||||
Inventory and promotional merchandise | 2,920 | 2,505 | ||||||
Prepaid expenses and other current assets | 792 | 603 | ||||||
Total current assets | 9,298 | 9,768 | ||||||
Property, plant and equipment, net | 2,650 | 2,280 | ||||||
Operating lease right-of-use assets | 1,949 | 2,190 | ||||||
Other assets | 7,013 | 7,733 | ||||||
Total assets | $ | 20,910 | $ | 21,971 | ||||
LIABILITIES AND EQUITY | ||||||||
Current debt | $ | 268 | $ | 32 | ||||
Accounts payable | 1,822 | 1,692 | ||||||
Operating lease liabilities | 365 | 379 | ||||||
Other accrued liabilities | 3,360 | 3,195 | ||||||
Total current liabilities | 5,815 | 5,298 | ||||||
Long-term debt | 5,144 | 5,537 | ||||||
Long-term operating lease liabilities | 1,868 | 2,151 | ||||||
Other noncurrent liabilities | 1,651 | 2,037 | ||||||
Total noncurrent liabilities | 8,663 | 9,725 | ||||||
Redeemable noncontrolling interest | 842 | 857 | ||||||
Total equity | 5,590 | 6,091 | ||||||
Total liabilities and equity | $ | 20,910 | $ | 21,971 | ||||
![]() |
Page 23 of 24
|
SELECT CASH FLOW DATA (Unaudited, except where noted) | ||||||||
Twelve Months Ended June 30 |
||||||||
($ in millions) | 2022 |
2021
(Audited)
|
||||||
Net earnings | $ | 2,408 | $ | 2,875 | ||||
Adjustments to reconcile net earnings to net cash flows from operating activities: | ||||||||
Depreciation and amortization | 727 | 651 | ||||||
Deferred income taxes | (149) | (230) | ||||||
Goodwill, other intangible and long-lived asset impairments | 241 | 188 | ||||||
Gain on previously held equity method investment | (1) | (847) | ||||||
Other items | 368 | 440 | ||||||
Changes in operating assets and liabilities: | ||||||||
Increase in accounts receivable, net | (10) | (398) | ||||||
Increase in inventory and promotional merchandise | (602) | (140) | ||||||
Decrease (increase) in other assets, net | (101) | 13 | ||||||
Increase in accounts payable and other liabilities | 159 | 1,079 | ||||||
Net cash flows provided by operating activities | $ | 3,040 | $ | 3,631 | ||||
Other Investing and Financing Sources (Uses): | ||||||||
Capital expenditures | $ | (1,040) | $ | (637) | ||||
Settlement of net investment hedges | 108 | (152) | ||||||
Payments for acquired businesses, net of cash acquired | (3) | (1,065) | ||||||
Purchases of investments | (10) | (42) | ||||||
Payments to acquire treasury stock | (2,309) | (733) | ||||||
Dividends paid | (840) | (753) | ||||||
Proceeds (repayments) of current debt, net | (4) | (744) | ||||||
Proceeds of long-term debt, net | (18) | 137 |
![]() |
Page 24 of 24
|